• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Mushrooms Evolved The Ability To Make Psilocybin Twice Independently, For Mysterious Reasons

September 26, 2025 by Deborah Bloomfield

Somehow, for reasons that are still unclear, the natural world gave rise to tiny mushrooms teeming with the psychoactive compound psilocybin. Even more astonishingly, the ability to produce this particular psychedelic didn’t evolve just once – it emerged at least twice independently.

Psilocybin is a naturally occurring psychedelic substance that profoundly alters consciousness and perception. While it can be used as a recreational (and illicit) drug to induce powerful trips, recent years have shown it also holds great promise in medicine, emerging as a potential treatment for therapy-resistant depression and other mental health conditions.

The chemical is most famously produced by around 165 different species belonging to the genus Psilocybe. However, it’s also made by part of another genus of mushroom-forming fungi, Inocybe, known as fiber caps.

For the first time, scientists in Germany and Austria have shown that the two fungal genera developed the ability to produce psilocybin at least twice independently of each other.

Psilocybe species make the substance using a known toolkit of enzymes. Surprisingly, they found that fiber cap mushrooms create it with a totally different biochemical arsenal, yet arrive at the same molecule.

“It was like looking at two different workshops, but both ultimately delivering the same product. In the fiber caps, we found a unique set of enzymes that have nothing to do with those found in Psilocybe mushrooms. Nevertheless, they all catalyze the steps necessary to form psilocybin,” Tim Schäfer, lead author of the study from the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (Leibniz-HKI), said in a statement.

This suggests the ability to produce psilocybin may be an example of convergent evolution – the process by which different organisms from different periods or regions independently evolve the same attributes or abilities due to similar evolutionary pressures. 

One well-known example is wings, which have evolved separately in birds, bats, insects, and other animals, all serving the same function of powered flight despite arising from very different parts of the tree of life. 

The question is, however, what drove the need for these two different fungi to co-evolve the same psychedelic compound?

“The real answer is: we don’t know,” said Professor Dirk Hoffmeister, head of the research group Pharmaceutical Microbiology at Friedrich Schiller University Jena and Leibniz-HKI. “Nature does nothing without reason. So there must be an advantage to both fiber cap mushrooms in the forest and Psilocybe species on manure or wood mulch producing this molecule – we just don’t know what it is yet.”

“One possible reason could be that psilocybin is intended to deter predators. Even the smallest injuries cause Psilocybe mushrooms to turn blue through a chemical chain reaction, revealing the breakdown products of psilocybin. Perhaps the molecule is a type of chemical defense mechanism,” added Hoffmeister.



Whatever the answer, the latest breakthrough could guide the way towards new, easier ways to synthesize psilocybin, as it shows there’s not one path towards making this mind-altering molecule.

“We hope that our results will contribute to the future production of psilocybin for pharmaceuticals in bioreactors without the need for complex chemical syntheses,” added Schäfer.

The study is published in the journal Angewandte Chemie International Edition.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. GrubMarket gobbles up $120M at a $1B+ pre-money valuation to take on the grocery supply chain
  2. Japanese octogenarian skateboarder learns new tricks
  3. Cyborgs V “Holdout Humans”: What The World Might Be Like If Our Species Survives For A Million Years
  4. Atlas V Carrying Final National Security Mission Launches Today – Watch Here

Source Link: Mushrooms Evolved The Ability To Make Psilocybin Twice Independently, For Mysterious Reasons

Filed Under: News

Primary Sidebar

  • The Only Living Mammals That Are Essentially Cold-Blooded Are Highly Social Oddballs
  • Hottest And Earliest Intergalactic Gas Ever Found In A Galaxy Cluster Challenges Our Models
  • Bayeux Tapestry May Have Been Mealtime Reading Material For Medieval Monks
  • Just 13 Letters: How The Hawaiian Language Works With A Tiny Alphabet
  • Astronaut Mouse Delivers 9 Pups A Month After Return To Earth
  • Meet The Moonfish, The World’s Only Warm-Blooded Fish That’s 5°C Hotter Than Its Environment
  • Neanderthals Repeatedly Dumped Horned Skulls In This Cave For An Unknown Ritual Purpose
  • Will The Earth Ever Stop Spinning?
  • Ammonites Survived The Asteroid That Killed The Dinosaurs, So What Killed Them Not Long After?
  • Why Do I Keep Zapping My Cat? The Strange Science Of Cats And Static Electricity
  • A Giant Volcano Off The Coast Of Oregon Is Scheduled To Erupt In 2026, JWST Finds The Best Evidence Yet Of A Lava World With A Thick Atmosphere, And Much More This Week
  • The UK’s Tallest Bird Faced Extinction In The 16th Century. Now, It’s Making A Comeback
  • Groundbreaking Discovery Of Two MS Subtypes Could Lead To New Targeted Treatments
  • “We Were So Lucky To Be Able To See This”: 140-Year Mystery Of How The World’s Largest Sea Spider Makes Babies Solved
  • China To Start New Hypergravity Centrifuge To Compress Space-Time – How Does It Work?
  • These Might Be The First Ever Underwater Photos Of A Ross Seal, And They’re Delightful
  • Mysterious 7-Million-Year-Old Ape May Be Earliest Hominin To Walk On Two Feet
  • This Spider-Like Creature Was Walking Around With A Tail 100 Million Years Ago
  • How Do GLP-1 Agonists Like Ozempic and Wegovy Work?
  • Evolution In Action: These Rare Bears Have Adapted To Be Friendlier And Less Aggressive
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2026 · Medical Market Report. All Rights Reserved.

Go to mobile version